These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1733 related articles for article (PubMed ID: 29091557)

  • 21. Two Japanese Patients With SMA Type 1 Suggest that Axonal-SMN May Not Modify the Disease Severity.
    Yamada H; Nishida Y; Maihara T; Sa'adah N; Harahap NI; Nurputra DK; Ar Rochmah M; Nishimura N; Saito T; Kubo Y; Saito K; Nishio H
    Pediatr Neurol; 2015 Jun; 52(6):638-41. PubMed ID: 25838041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world multidisciplinary outcomes of onasemnogene abeparvovec monotherapy in patients with spinal muscular atrophy type 1: experience of the French cohort in the first three years of treatment.
    Desguerre I; Barrois R; Audic F; Barnerias C; Chabrol B; Davion JB; Durigneux J; Espil-Taris C; Gomez-Garcia de la Banda M; Guichard M; Isapof A; Nougues MC; Laugel V; Le Goff L; Mercier S; Pervillé A; Richelme C; Thibaud M; Sarret C; Schweitzer C; Testard H; Trommsdorff V; Vanhulle C; Walther-Louvier U; Altuzarra C; Chouchane M; Ropars J; Quijano-Roy S; Cances C
    Orphanet J Rare Dis; 2024 Sep; 19(1):344. PubMed ID: 39272200
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CIM Journal Club: Gene therapy for spinal muscular atrophy Comment on Mendell et al. N Engl J Med 2017;377:1713-22.
    Schneider R
    Clin Invest Med; 2018 Mar; 41(1):E31-E33. PubMed ID: 29603689
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between the SMN2 gene copy number and clinical characteristics of patients with spinal muscular atrophy with homozygous deletion of exon 7 of the SMN1 gene.
    Zarkov M; Stojadinović A; Sekulić S; Barjaktarović I; Perić S; Keković G; Drasković B; Stević Z
    Vojnosanit Pregl; 2015 Oct; 72(10):859-63. PubMed ID: 26665550
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study.
    Weiß C; Ziegler A; Becker LL; Johannsen J; Brennenstuhl H; Schreiber G; Flotats-Bastardas M; Stoltenburg C; Hartmann H; Illsinger S; Denecke J; Pechmann A; Müller-Felber W; Vill K; Blaschek A; Smitka M; van der Stam L; Weiss K; Winter B; Goldhahn K; Plecko B; Horber V; Bernert G; Husain RA; Rauscher C; Trollmann R; Garbade SF; Hahn A; von der Hagen M; Kaindl AM
    Lancet Child Adolesc Health; 2022 Jan; 6(1):17-27. PubMed ID: 34756190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice.
    Dominguez E; Marais T; Chatauret N; Benkhelifa-Ziyyat S; Duque S; Ravassard P; Carcenac R; Astord S; Pereira de Moura A; Voit T; Barkats M
    Hum Mol Genet; 2011 Feb; 20(4):681-93. PubMed ID: 21118896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-Life Outcome After Gene Replacement Therapy for Spinal Muscular Atrophy: A Multicenter Experience.
    Tokatly Latzer I; Sagi L; Lavi R; Aharoni S; Bistritzer J; Noyman I; Ginsburg M; Lev-Or A; Katzenellenbogen S; Nevo Y; Fattal-Valevski A
    Pediatr Neurol; 2023 Jul; 144():60-68. PubMed ID: 37149951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natural history of infantile-onset spinal muscular atrophy.
    Kolb SJ; Coffey CS; Yankey JW; Krosschell K; Arnold WD; Rutkove SB; Swoboda KJ; Reyna SP; Sakonju A; Darras BT; Shell R; Kuntz N; Castro D; Parsons J; Connolly AM; Chiriboga CA; McDonald C; Burnette WB; Werner K; Thangarajh M; Shieh PB; Finanger E; Cudkowicz ME; McGovern MM; McNeil DE; Finkel R; Iannaccone ST; Kaye E; Kingsley A; Renusch SR; McGovern VL; Wang X; Zaworski PG; Prior TW; Burghes AHM; Bartlett A; Kissel JT;
    Ann Neurol; 2017 Dec; 82(6):883-891. PubMed ID: 29149772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A second chance.
    Kaiser J
    Science; 2017 Nov; 358(6363):582-585. PubMed ID: 29097531
    [No Abstract]   [Full Text] [Related]  

  • 30. Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy.
    Valori CF; Ning K; Wyles M; Mead RJ; Grierson AJ; Shaw PJ; Azzouz M
    Sci Transl Med; 2010 Jun; 2(35):35ra42. PubMed ID: 20538619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND).
    Glanzman AM; McDermott MP; Montes J; Martens WB; Flickinger J; Riley S; Quigley J; Dunaway S; O'Hagen J; Deng L; Chung WK; Tawil R; Darras BT; Yang M; Sproule D; De Vivo DC; Kaufmann P; Finkel RS; ;
    Pediatr Phys Ther; 2011; 23(4):322-6. PubMed ID: 22090068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Translational fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy.
    Passini MA; Bu J; Richards AM; Treleaven CM; Sullivan JA; O'Riordan CR; Scaria A; Kells AP; Samaranch L; San Sebastian W; Federici T; Fiandaca MS; Boulis NM; Bankiewicz KS; Shihabuddin LS; Cheng SH
    Hum Gene Ther; 2014 Jul; 25(7):619-30. PubMed ID: 24617515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy.
    Mendell JR; Al-Zaidy SA; Lehman KJ; McColly M; Lowes LP; Alfano LN; Reash NF; Iammarino MA; Church KR; Kleyn A; Meriggioli MN; Shell R
    JAMA Neurol; 2021 Jul; 78(7):834-841. PubMed ID: 33999158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG).
    Finkel RS; Darras BT; Mendell JR; Day JW; Kuntz NL; Connolly AM; Zaidman CM; Crawford TO; Butterfield RJ; Shieh PB; Tennekoon G; Brandsema JF; Iannaccone ST; Shoffner J; Kavanagh S; Macek TA; Tauscher-Wisniewski S
    J Neuromuscul Dis; 2023; 10(3):389-404. PubMed ID: 36911944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene transfer therapy in children with spinal muscular atrophy: A single-center experience with a cohort of 25 children.
    Chencheri N; Alexander G; Nugud A; Majadas E; Salim H; Prudhomme K; DeJager N; Janardhanan VS; Elbashir H
    Muscle Nerve; 2023 Sep; 68(3):269-277. PubMed ID: 37392188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy.
    De Sanctis R; Pane M; Coratti G; Palermo C; Leone D; Pera MC; Abiusi E; Fiori S; Forcina N; Fanelli L; Lucibello S; Mazzone ES; Tiziano FD; Mercuri E
    Neuromuscul Disord; 2018 Jan; 28(1):24-28. PubMed ID: 29174525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preemptive dual therapy for children at risk for infantile-onset spinal muscular atrophy.
    Matesanz SE; Brigatti KW; Young M; Yum SW; Strauss KA
    Ann Clin Transl Neurol; 2024 Jul; 11(7):1868-1878. PubMed ID: 38817128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Newborn screening for spinal muscular atrophy in Australia: a non-randomised cohort study.
    Kariyawasam DS; D'Silva AM; Sampaio H; Briggs N; Herbert K; Wiley V; Farrar MA
    Lancet Child Adolesc Health; 2023 Mar; 7(3):159-170. PubMed ID: 36669516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Onasemnogene Abeparvovec: First Global Approval.
    Hoy SM
    Drugs; 2019 Jul; 79(11):1255-1262. PubMed ID: 31270752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene therapy field hit by fresh safety concern.
    Kaiser J
    Science; 2018 Feb; 359(6376):621. PubMed ID: 29439221
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 87.